Literature DB >> 9158464

Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study.

C J Weir1, G D Murray, A G Dyker, K R Lees.   

Abstract

OBJECTIVE: To determine whether raised plasma glucose concentration independently influences outcome after acute stroke or is a stress response reflecting increased stroke severity.
DESIGN: Long-term follow up study of patients admitted to an acute stroke unit.
SETTING: Western Infirmary, Glasgow.
SUBJECTS: 811 patients with acute stroke confirmed by computed tomography. Analysis was restricted to the 750 non-diabetic patients. MAIN OUTCOME MEASURES: Survival time and placement three months after stroke.
RESULTS: 645 patients (86%) had ischaemic stroke and 105 patients (14%) haemorrhagic stroke. Cox's proportional hazards modelling with stratification according to Oxfordshire Community Stroke Project categories identified increased age (relative hazard 1.36 per decade; 95% confidence interval 1.21 to 1.53), haemorrhagic stroke (relative hazard 1.67; 1.22 to 2.28), time to resolution of symptoms > 72 hours (relative hazard 2.15; 1.15 to 4.05), and hyperglycaemia (relative hazard 1.87; 1.43 to 2.45) as predictors of mortality. The effect of glucose concentration on survival was greatest in the first month.
CONCLUSIONS: Plasma glucose concentration above 8 mmol/l after acute stroke predicts a poor prognosis after correcting for age, stroke severity, and stroke subtype. Raised plasma glucose concentration is therefore unlikely to be solely a stress response and should arguably be treated actively. A randomised trial is warranted.

Entities:  

Mesh:

Year:  1997        PMID: 9158464      PMCID: PMC2126557          DOI: 10.1136/bmj.314.7090.1303

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  86 in total

1.  Relation between troponin T concentration and mortality in patients presenting with an acute stroke: observational study.

Authors:  P James; C J Ellis; R M Whitlock; A R McNeil; J Henley; N E Anderson
Journal:  BMJ       Date:  2000-06-03

Review 2.  Medical therapy for acute ischemic stroke.

Authors:  L B Goldstein
Journal:  Curr Atheroscler Rep       Date:  2001-07       Impact factor: 5.113

3.  Acute Ischemic Stroke.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-05       Impact factor: 3.598

4.  Hemorrhage rates and outcomes when using up to 100 mg intra-arterial t-PA for thrombolysis in acute ischemic stroke.

Authors:  G A Christoforidis; A P Slivka; C Karakasis; Y Mohammad; B Avutu; M Yang; E C Bourekas; D W Chakeres; H W Slone; W T Yuk
Journal:  Interv Neuroradiol       Date:  2010-10-25       Impact factor: 1.610

5.  Secondary prevention for stroke and transient ischaemic attacks: Horizons needs expanding.

Authors:  Sumantra Ray; Alexander S F Doney; Ronald S MacWalter
Journal:  BMJ       Date:  2004-04-10

6.  Arteriographic demonstration of slow antegrade opacification distal to a cerebrovascular thromboembolic occlusion site as a favorable indicator for intra-arterial thrombolysis.

Authors:  G A Christoforidis; Y Mohammad; B Avutu; A Tejada; A P Slivka
Journal:  AJNR Am J Neuroradiol       Date:  2006-08       Impact factor: 3.825

7.  Clinical predictors and management of hemorrhagic transformation.

Authors:  Raphaella E Weiser; Kevin N Sheth
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

8.  Results of the MRI substudy of the intravenous magnesium efficacy in stroke trial.

Authors:  Chelsea S Kidwell; Kennedy R Lees; Keith W Muir; Christopher Chen; Stephen M Davis; Deidre A De Silva; Christopher J Weir; Sidney Starkman; Jeffry R Alger; Jeffrey L Saver
Journal:  Stroke       Date:  2009-03-19       Impact factor: 7.914

Review 9.  Drug therapy for acute ischaemic stroke: risks versus benefits.

Authors:  R I Lindley
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

10.  Clinical determinants of infarct pattern subtypes in large vessel atherosclerotic stroke.

Authors:  Oh Young Bang; Bruce Ovbiagele; David S Liebeskind; Lucas Restrepo; Sa Rah Yoon; Jeffrey L Saver
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.